Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.60 |
| ▸ | CTSS | P25774 | 6/20 | 0.53 |
| ▸ | CTSK | P43235 | 5/20 | 0.53 |
| ▸ | CTSB | P07858 | 4/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.48 |
| ▸ | ITGAV | P06756 | 1/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | BCL2 | P10415 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28789425 | 1.00 | ACE (0.60) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL29722671 | 1.00 | ACE (0.60) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL23203156 | 0.90 | ACE (0.59) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL10156301 | 0.90 | KLK5 (0.55) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL4546558 | 0.88 | CTSS (0.52) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL31106950 | 0.88 | CTSS (0.52) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL9955453 | 0.85 | ACE (0.59) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL1826278 | 0.84 | ACE (0.58) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL14999575 | 0.83 | ITGB1 (0.45) | ACEITGB1ALDH1A1 | |
| SCHEMBL2803616 | 0.83 | ACE (0.65) | ACECTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114656379-B | Synthesis method of ritalst intermediate | 成都道合尔医药技术有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-114656379-A | Synthetic method of sitagliptin intermediate | 成都道合尔医药技术有限公司 | 2022-06-24 | — | — | CN | claimed |
| CN-114656379-B | Synthesis method of ritalst intermediate | 成都道合尔医药技术有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-114656379-B | Synthesis method of ritalst intermediate | 成都道合尔医药技术有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-117776984-A | Preparation method of ritalst intermediate | 浙江博崤生物制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-3807268-B1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | OLON SPA (IT) | 2024-01-24 | — | — | EP | disclosed |
| US-20230331711-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | BAUSCH + LOMB IRELAND LIMITED (IE) | 2023-10-19 | — | — | US | disclosed |
| US-20230331711-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | BAUSCH + LOMB IRELAND LIMITED (IE) | 2023-10-19 | — | — | US | disclosed |
| CN-114656379-A | Synthetic method of sitagliptin intermediate | 成都道合尔医药技术有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-114656379-A | Synthetic method of sitagliptin intermediate | 成都道合尔医药技术有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-11345683-B2 | Process for the preparation of lifitegrast | AUROBINDO PHARMA LTD (IN) | 2022-05-31 | — | — | US | disclosed |
| US-8378105-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8378105-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8367701-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367701-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120107404-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARCODE BIOSCIENCE INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8080562-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080562-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110092707-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARCODE CORPORATION (US) | 2011-04-21 | — | — | US | disclosed |
| US-20090298869-A1 | Crystalline pharmaceutical and methods of preparation and use thereof | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345683-B2 | Process for the preparation of lifitegrast | LIFR, IDUA, LMTK2 | ACE 2136/4885CTSS 2463/4885CTSK 1803/4885 |
| US-20120107404-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | VCAM1, ICAM1, HLA-DRB1 | ACE 1043/4885CTSS 658/4885CTSK 978/4885 |
| US-20090298869-A1 | Crystalline pharmaceutical and methods of preparation and use thereof | VCAM1, ICAM1, HLA-DRB1 | ACE 1043/4885CTSS 658/4885CTSK 978/4885 |
| US-20230331711-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | VCAM1, ICAM1, HLA-DRB1 | ACE 1043/4885CTSS 658/4885CTSK 978/4885 |
| US-20110092707-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | VCAM1, ICAM1, HLA-DRB1 | ACE 1043/4885CTSS 658/4885CTSK 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.